Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOMS: Strategies to Reduce Nevirapine Resistance
NCT00099632Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2006
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of lamivudine + zidovudine, emtricitabine + tenofovir disoproxil, lopinavir + ritonavir in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2006; status: completed.
02
Drugs
lamivudine + zidovudineemtricitabine + tenofovir disoproxillopinavir + ritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00099632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099632.